Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Apr 2011

Zucali Paolo Andrea, Giovannetti Elisa, Destro Annarita, Mencoboni Manlio, Ceresoli Giovanni Luca, Gianoncelli Letizia, Lorenzi Elena, De Vincenzo Fabio, Simonelli Matteo, Perrino Matteo, Bruzzone Andrea, Thunnissen Erik, Tunesi Gianni, Giordano Laura, Roncalli Massimo, Peters Godefridus J, Santoro Armando

Abstract excerpt

PURPOSE: The pemetrexed/platinum agent combination represents the standard of care in first-line treatment for malignant pleural mesothelioma (MPM). However, there are no established indicators of responsiveness that can be used to optimize the treatment. This retrospective study aimed to assess...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carboplatin
Share to Endonucleases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glutamates

Share to Guanine

Share to Mesothelioma

Share to Pemetrexed

Share to Pleural Neoplasms

Share to Thymidylate Synthase

Source

Identifiers

PMID: 21262916
DOI: 10.1158/1078-0432.CCR-10-2873

Genes

ERCC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-21262916-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin.PMID 21262916Read ↗

Molecular Resistance Fingerprint of Pemetrexed and Platinum in a Long-Term Survivor of MesotheliomaSemantic proximity Read ↗

Association of thymidylate synthase gene 3'-untranslated region polymorphism with sensitivity of non-small cell lung cancer to pemetrexed treatment: TS gene polymorphism and pemetrexed sensitivity in NSCLC.Semantic proximity Read ↗

Survey and biological insights of pemetrexed-related therapeutic improvement in mesothelioma: The Nancy Centre of Biological Resources' Mesothelioma Cohort.Semantic proximity Read ↗

Phase II trial of carboplatin and pemetrexed as first-line chemotherapy for non-squamous non-small cell lung cancer, and correlation between the efficacy/toxicity and genetic polymorphisms associated with pemetrexed metabolism: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0902.Semantic proximity Read ↗

ERCC1, MLH1, MSH2, MSH6, and βIII-Tubulin: Resistance Proteins Associated With Response and Outcome to Platinum-based Chemotherapy in Malignant Pleural MesotheliomaSemantic proximity Read ↗

X-ray cross-complementing group 1 and thymidylate synthase polymorphisms might predict response to chemoradiotherapy in rectal cancer patients.Semantic proximity Read ↗

Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations.Semantic proximity Read ↗

Upregulation of Thymidylate Synthase Induces Pemetrexed Resistance in Malignant Pleural MesotheliomaSemantic proximity Read ↗

Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin.Semantic proximity Read ↗

The influence of platinum pathway polymorphisms on the outcome in patients with malignant mesotheliomaSemantic proximity Read ↗

Pemetrexed-based chemotherapy in advanced lung adenocarcinoma patients with different EGFR genotypes.Semantic proximity Read ↗

Folic acid phenotype (FAP) is a superior biomarker predicting response to pemetrexed-based chemotherapy in malignant pleural mesothelioma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.